Parkinson's Disease (PD) Animal Model Development Services
As a specialized Contract Research Organization (CRO), our principal activities are centered within the neurobiology sector, with a dedicated concentration on developing and validating sophisticated animal models crucial for advancing Parkinson's disease (PD) research. Our institution provides investigators access to an extensive portfolio of preclinical PD modeling systems. This repertoire encompasses widely utilized, classical neurotoxin-based paradigms—specifically, the MPTP-induced mouse model and the unilateral 6-OHDA lesion model, typically established in rodents. Furthermore, our offerings include genetically defined models, prominently featuring various α-synuclein transgenic mouse lines.
These diverse models are meticulously characterized; they are engineered, based on current understanding, to comprehensively recapitulate the salient neuropathological hallmarks and progressive neurodegenerative processes intrinsic to Parkinson's disease. Consequently, they serve as vital platforms for mechanistic studies and therapeutic candidate evaluation. Our expert services extend beyond model provision to constitute a complete, integrated workflow solution. This comprehensive support spans the entire research trajectory: beginning with collaborative, strategic experimental design and protocol optimization, proceeding through meticulous in-life study execution, and culminating in rigorous, in-depth data analysis and interpretation. Specifically, the available analytical services incorporate a battery of critical assessments, including detailed behavioral phenotyping (assessing parameters such as motor coordination, locomotor activity, and potentially cognitive function), quantitative neurochemical assays to measure key neurotransmitter levels and turnover, thorough histopathological examination of relevant central nervous system structures, and advanced in vivo or ex vivo neuroimaging techniques where applicable. This integrated approach aims to deliver robust, interpretable datasets tailored to specific research objectives within the field of Parkinson's disease.
How Our PD Animal Model Can Assist Your Project?
Our PD animal model development service provides tailored solutions to address your specific research needs in PD drug discovery. We deliver robust, well-characterized animal models and comprehensive data packages to support your preclinical studies.
Deliverables, Solutions, and Key Problem-Solving Capabilities:
- Development of customized animal models that accurately reflect specific aspects of PD pathology, including motor and non-motor symptoms.
- Comprehensive in vivo pharmacology studies to evaluate the efficacy and safety of novel therapeutic candidates.
- Detailed characterization of disease progression and treatment response using advanced behavioral, biochemical, and histological techniques.
- Identification of potential biomarkers for PD and assessment of their modulation by therapeutic interventions.
Discover How We Can Help - Request a Consultation
Workflow
Our streamlined workflow ensures efficient and reliable PD animal model development:
Required Starting Materials:
- To initiate a project, clients typically provide:
- Target compound information, including chemical structure and desired dosage regimen.
- Clear specification of research aims, primary endpoints, and essential study design parameters.
- Provision of pertinent background data, notably including results from relevant prior in vitro or in vivo investigations.
Final Deliverables:
- Clients receive:
- A comprehensive study report, including detailed methodology, results, statistical analysis, and interpretation.
- Raw and processed data, including behavioral scores, biochemical measurements, histological images, and statistical outputs.
- Well-characterized animal models, ready for further investigation.
- Estimated Timeframe:
The typical timeframe for this service ranges from 8 to 20 weeks, depending on the complexity of the model, the scope of the study, and specific client requirements. Factors that may influence the duration include:
- The specific animal model selected.
- The number of experimental groups and endpoints.
- The need for custom model generation.
Why Choose Us?
Our PD service stands out due to our:
- Extensive Expertise: Our team comprises experienced scientists with deep knowledge of PD pathogenesis and animal model development.
- Customized Solutions: We tailor our services to meet your unique research needs, ensuring the most relevant and effective study design.
- Comprehensive Capabilities: We offer a wide range of animal models, advanced technologies, and comprehensive data analysis.
- High-Quality Standards: We adhere to rigorous quality control measures to ensure the reliability and reproducibility of our results.
- Proven Track Record: Creative Biolabs has a history of successful collaborations with leading pharmaceutical and biotechnology companies. Published Data supports our expertise.
Experience the Advantage - Get a Quote Today
Types of our PD Animal Models
At Creative Biolabs, we offer a variety of PD animal models, including:
- 6-OHDA-Induced Mouse Model
- MPTP-Induced Mouse Model
- hA53T-α-syn Induced Mouse Model
- Genetically Engineered Models
- Preformed Fibril (PFF) Models
Customer Reviews
"Using Creative Biolabs' PD animal models in our research has significantly improved the translatability of our preclinical findings to the clinic." - [10 Months], J***s
" Creative Biolabs' expertise in model generation and characterization was invaluable in accelerating our drug discovery program." - [14 Months], Dr. L***y
"The comprehensive data package provided by Creative Biolabs allowed us to confidently advance our lead compound into clinical trials." - [18 Months], Prof. S***h
What We Can Offer
- Customized Model Development: We specialize in tailoring PD animal models to your precise research needs, ensuring the model accurately reflects the specific aspects of the disease you are investigating.
- Comprehensive Solutions: CBL offers a complete solution, from initial consultation and study design to final data analysis and reporting.
- Advanced Techniques: We utilize cutting-edge techniques, including genetic engineering, toxin administration, and preformed fibril injection, to generate a wide range of PD models.
- Rigorous Quality Control: Our well-established quality system, Quality-by-Design (QbD), and process analytical techniques (PAT) ensure the highest standards of data reliability and reproducibility.
- Expert Consultation: Benefit from the expertise of our seasoned scientists, who provide guidance on study design, model selection, and data interpretation.
- Data Transparency: We provide comprehensive study reports with detailed methodology, results, and statistical analysis, along with all raw and processed data.
- Focus on Translational Relevance: CBL emphasizes the development of animal models with high translational relevance to human PD, facilitating the development of effective therapies.
Related Services
We also offer a range of complementary services that may be valuable for your PD research, including:
- In Vitro PD Cell Models
- Behavioral Testing
- Custom Antibody Development
Contact our team today to discuss your project and learn how we can help you achieve your research goals.
FAQs
Q Regarding Parkinson's Disease (PD) investigations, does CBL possess the capability to generate bespoke animal models tailored to specific research directives?
Q Upon study completion, what types of data deliverables and documentation are typically provided to the client?
Q In comparison to other commercially available options, what are the distinguishing characteristics and principal advantages of CBL's PD animal models?
- iNeuMab™ Anti-Amyloid Beta 1-15 Antibody (NRP-0422-P867) (Cat#: NRP-0422-P867)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1684) (Cat#: NRP-0422-P1684)
- iNeuMab™ Anti-EPHB2 Antibody (NRP-0422-P1220) (Cat#: NRP-0422-P1220)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3503) (Cat#: NRZP-1022-ZP3503)
- iNeuMab™ Anti-ApoC3 BBB Shuttle Antibody (NRZP-1022-ZP3505) (Cat#: NRZP-1022-ZP3505)
- iNeuMab™ Anti-Integrin αvβ8 BBB Shuttle Antibody (NRZP-1222-ZP1218) (Cat#: NRZP-1222-ZP1218)
- iNeuMab™ Anti-SEZ6 Antibody (NRP-0422-P515) (Cat#: NRP-0422-P515)
- iNeuMab™ Anti-Alpha Synuclein BBB Shuttle Antibody (NRZP-1022-ZP4050) (Cat#: NRZP-1022-ZP4050)
- iNeuMab™ Mouse Anti-SHANK3 Monoclonal Antibody (CBP929) (Cat#: NAB-0720-Z3477)
- iNeuMab™ Anti-Tau Antibody (NRP-0422-P1683) (Cat#: NRP-0422-P1683)
- Human Retinal Epithelial Cell ARPE-19 (Cat#: NCL2110P069)
- iNeu™ Human Schwann Cell (Cat#: NCL-2103-P63)
- Rat Glioma Cell Line C6 (Cat#: NCL2110P346)
- Human Glial (Oligodendrocytic) Hybrid Cell Line (MO3.13) (Cat#: NCL-2108P34)
- Human Brain Microvascular Endothelial Cells (Cat#: NCL-2103-P133)
- Mouse Midbrain Dopaminergic Neuron Cell MN9D (Cat#: NCL2110P059)
- iNeu™ Human Oligodendrocyte Progenitor Cells (OPCs) (Cat#: NCL-2103-P49)
- Mouse Glioma Cell Line GL-261-Luc (Cat#: NCL-2108P06)
- Human Microglia Cell Line HMC3, Immortalized (Cat#: NCL-2108P38)
- Green Fluorescent BACE1 Cell Lines (Cat#: NCL2110P214)
- Human Tau Aggregation Kit (Cat#: NRP-0322-P2173)
- Beta Amyloid (1-42), Aggregation Kit (Cat#: NRZP-0323-ZP200)
- Human GFAP ELISA Kit [Colorimetric] (Cat#: NPP2011ZP383)
- Amyloid beta 1-42 Kit (Cat#: NRP-0322-P2170)
- Alpha-Synuclein Aggregation Assay Kit (Cat#: NRZP-1122-ZP37)
- Alpha Synuclein Aggregation Kit (Cat#: NRZP-1122-ZP15)
- Beta Amyloid (1-40), Aggregation Kit (Cat#: NRZP-0323-ZP199)
- Human Poly ADP ribose polymerase,PARP Assay Kit (Cat#: NRZP-1122-ZP62)
- AAV2 Full Capsids, Reference Standards (Cat#: NTC2101070CR)
- VSV-eGFP (Cat#: NTA-2011-ZP20)
- Dextran, NHS Activated (Cat#: NRZP-0722-ZP124)
- Tau Antisense Oligonucleotide (IONIS-MAPTRx) (Cat#: NV-2106-P29)
- Rat Parkinson disease (autosomal recessive, juvenile) 2, parkin (Park2) (NM_020093) ORF clone/lentiviral particle, Myc-DDK Tagged (Cat#: NEP-0621-R0041)
- Mouse SOD1 shRNA Silencing Adenovirus (Cat#: NV-2106-P14)
- Human presenilin 1 (PSEN1), transcript variant 2 (NM_007318) ORF clone, TurboGFP Tagged (Cat#: NEP-0421-R0140)
- Human huntingtin (HTT) (NM_002111) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0497)
- Mouse Parkinson disease (autosomal recessive, early onset) 7 (Park7) (NM_020569) clone, Untagged (Cat#: NEP-0621-R0133)
- ABCA1 Antisense Oligonucleotide (NV-2106-P27) (Cat#: NV-2106-P27)
- Human huntingtin-associated protein 1 (HAP1) transcript variant 2 (NM_177977) ORF clone, Myc-DDK Tagged (Cat#: NEP-0521-R0676)
- Human superoxide dismutase 3, extracellular (SOD3) (NM_003102) ORF clone, Untagged (Cat#: NEP-0521-R0808)
- Human superoxide dismutase 1, soluble (SOD1) (NM_000454) ORF clone, TurboGFP Tagged (Cat#: NEP-0521-R0748)
- NeuroBiologics™ Pig Cerebrospinal Fluid (Cat#: NRZP-0822-ZP498)
- NeuroBiologics™ Rat Cerebrospinal Fluid (Cat#: NRZP-0822-ZP496)
- NeuroBiologics™ Mouse Cerebrospinal Fluid (Cat#: NRZP-0822-ZP497)
- NeuroBiologics™ Monkey Cerebrospinal Fluid (Cat#: NRZP-0822-ZP495)
- NeuroBiologics™ Human Cerebrospinal Fluid (Cat#: NRZP-0822-ZP491)
- NeuroPro™ Anti-EPO BBB Shuttle Protein (Cat#: NRZP-0423-ZP508)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP502)
- NeuroPro™ Anti-Erythropoietin BBB Shuttle Protein (Cat#: NRZP-0423-ZP499)
- NeuroPro™ Anti-IDS BBB Shuttle Protein (Cat#: NRZP-0423-ZP503)
- NeuroPro™ Anti-PON1 BBB Shuttle Protein (Cat#: NRZP-0423-ZP507)
- NeuroPro™ Anti-ASA BBB Shuttle Protein (Cat#: NRZP-0423-ZP504)
- NeuroPro™ Anti-IDUA BBB Shuttle Protein (Cat#: NRZP-0423-ZP498)
- NeuroPro™ Anti-GDNF BBB Shuttle Protein (Cat#: NRZP-0423-ZP509)
- NeuroPro™ Anti-TNFR BBB Shuttle Protein (Cat#: NRZP-0423-ZP510)
- NeuroPro™ Anti-SGSH BBB Shuttle Protein (Cat#: NRZP-0423-ZP505)